阿斯利康积极布局未来。3月17日,阿斯利康官宣了两笔交易。一是宣布收购体内细胞疗法公司EsoBiotec,代价为4.25亿美元首付款,以及最高5.75亿美元的基于开发和监管里程碑付款。二是和Alteogen Inc.就ALT-B4达成独家许可协议,这是一种利用Hybrozyme™平台技术的新型透明质酸酶,阿斯利康将使用ALT-B4开发和商业化多种肿瘤药物的皮下制剂。艾美疫苗发布2024年业绩预告。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.